NYSE:BMY News 10 October 2025

Bristol-Myers Squibb (BMY) Stock Today: Celgene Lawsuit Shock, ASH 2025 Momentum and 2026 Forecasts

On December 2, 2025, Bristol-Myers Squibb (NYSE: BMY) found itself at the center of two very different storylines: a revived $6.7 billion Celgene lawsuit and strong hematology data at ASH 2025. Together with a hefty dividend and low valuation multiples,

3 December 2025

Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

Bristol-Myers Squibb (NYSE: BMY) has suddenly become one of the most eventful big pharma names to watch as of December 1, 2025. A major lawsuit has been allowed to proceed, new cell therapy approvals are landing, hematology data at ASH

2 December 2025

Investment Analysis · Lawsuits · Market Forecast · NYSE:BMY · Pharmaceutical Industry · Stocks

Bristol-Myers Squibb (BMY) Stock on November 29, 2025: 5.4% Dividend, Heavy Institutional Buying and a ‘Hold’ Consensus

Bristol-Myers Squibb (NYSE: BMY) spent Saturday, November 29, 2025 out of the trading spotlight—U.S. markets were closed—but very much in the headlines. A cluster of fresh reports focused on three themes: a fat 5.4% dividend yield, big institutional investors quietly

30 November 2025

Dividends · Institutional Investors · Investment Analysis · NYSE:BMY · Pharmaceutical Companies · Stock Market

BMY Stock Soars on Factor XIa Catalyst and Hematology Investor Event (Nov. 24, 2025)

Published: November 24, 2025Ticker: Bristol Myers Squibb Company (NYSE: BMY) Key takeaways This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. BMY stock today: a 4% move

24 November 2025

Biotech · Investing · Market News · NYSE:BMY · Pharmaceuticals · Stocks

Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb and Johnson & Johnson end a key Phase 3 heart study for milvexian, sending BMY stock lower even as the pharma giant leans on a strong growth portfolio and fresh financing firepower. Bristol-Myers Squibb Company (NYSE: BMY)

14 November 2025

Financial Analysis · Healthcare · Investment News · NYSE:BMY · NYSE:JNJ · Pharmaceuticals · Stock Market

5 NYSE Stocks to Watch Today (November 14, 2025): WMT, MRK, BMY, NSC, VRT

Global equities are under pressure again today as the tech-led selloff rolls on and traders dial back expectations for a near‑term Federal Reserve rate cut. U.S. futures were down sharply ahead of the open and the major indices have extended

14 November 2025

Blue Chip Stocks · Daily Market Update · Investments · NYSE · NYSE:BMY · NYSE:MRK · NYSE:NSC · NYSE:VRT · NYSE:WMT · Stock Watchlist

Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Financing & balance sheet: euro notes + tender offer Bristol‑Myers Squibb priced €5 billion in senior unsecured notes across five tranches — €750M 2030 (2.973%), €1.15B 2033 (3.363%), €1.15B 2038 (3.857%), €750M 2045 (4.289%), and €1.2B 2055 (4.581%) — with

9 November 2025

Financial Results · Legal Updates · Market Outlook · Mergers & Acquisitions · NASDAQ:BNTX · NYSE:BMY · Pharma News

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 15.10.2025

BMY shines under Partha Mohanram’s P/B Growth model with an 88% rating October 15, 2025, 11:18 PM EDT. Validea’s guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) shows the stock scoring highest under Partha Mohanram’s P/B Growth Investor model, a

15 October 2025

Economy · Financial News · Investing · Market Analysis · NYSE:BMY · Stock Market

Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

In-Depth Analysis BMS’s acquisition of Orbital Therapeutics marks a deliberate push into autoimmune disease treatment via advanced cell therapy. Orbital, founded in 2022 by leaders in RNA and immunology, has built a proprietary RNA platform combining circular and linear RNA

10 October 2025

Biotech · Healthcare Industry · Investment · Mergers & Acquisitions · NYSE:BMY · Pharma News

NYSE:BMY News 10 October 2025 - 3 December 2025